| Year |
Citation |
Score |
| 2024 |
Ali S, Wang P, Murphy RE, Allen JA, Zhou J. Orphan GPR52 as an emerging neurotherapeutic target. Drug Discovery Today. 103922. PMID 38387741 DOI: 10.1016/j.drudis.2024.103922 |
0.342 |
|
| 2023 |
Bolinger AA, Frazier A, La JH, Allen JA, Zhou J. Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target. Acs Chemical Neuroscience. PMID 37676000 DOI: 10.1021/acschemneuro.3c00479 |
0.392 |
|
| 2022 |
Wang P, Felsing DE, Chen H, Raval SR, Allen JA, Zhou J. Retraction of "Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists". Acs Medicinal Chemistry Letters. 13: 989. PMID 35707156 DOI: 10.1021/acsmedchemlett.2c00197 |
0.757 |
|
| 2020 |
Wang P, Felsing DE, Chen H, Stutz SJ, Murphy RE, Cunningham KA, Allen JA, Zhou J. Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior. Journal of Medicinal Chemistry. PMID 33198466 DOI: 10.1021/acs.jmedchem.0c01498 |
0.766 |
|
| 2019 |
Land MA, Chapman HL, Davis-Reyes BD, Felsing DE, Allen JA, Moeller FG, Elferink LA, Cunningham KA, Anastasio NC. Serotonin 5-HT Receptor Cys23Ser Single Nucleotide Polymorphism Associates with Receptor Function and Localization In Vitro. Scientific Reports. 9: 16737. PMID 31723224 DOI: 10.1038/S41598-019-53124-2 |
0.753 |
|
| 2019 |
Felsing DE, Jain MK, Allen JA. Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics. Current Topics in Medicinal Chemistry. 19: 1365-1380. PMID 31553283 DOI: 10.2174/1568026619666190712210903 |
0.773 |
|
| 2019 |
Wang P, Felsing DE, Chen H, Raval SR, Allen JA, Zhou J. Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists. Acs Medicinal Chemistry Letters. 10: 792-799. PMID 31098001 DOI: 10.1021/Acsmedchemlett.9B00050 |
0.777 |
|
| 2018 |
Ye N, Li B, Mao Q, Wold EA, Tian S, Allen JA, Zhou J. Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. Acs Chemical Neuroscience. PMID 30540906 DOI: 10.1021/Acschemneuro.8B00572 |
0.388 |
|
| 2018 |
Felsing DE, Anastasio NC, Miszkiel JM, Gilbertson SR, Allen JA, Cunningham KA. Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction. Plos One. 13: e0203137. PMID 30157263 DOI: 10.1371/Journal.Pone.0203137 |
0.773 |
|
| 2018 |
Sampson CM, Kasper JM, Felsing DE, Raval SR, Ye N, Wang P, Patrikeev I, Rytting E, Zhou J, Allen JA, Hommel JD. Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal Models. Pharmacology Research & Perspectives. 6: e00425. PMID 30151213 DOI: 10.1002/Prp2.425 |
0.74 |
|
| 2018 |
Gray DL, Allen JA, Mente S, O'Connor RE, DeMarco GJ, Efremov I, Tierney P, Volfson D, Davoren J, Guilmette E, Salafia M, Kozak R, Ehlers MD. Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Nature Communications. 9: 674. PMID 29445200 DOI: 10.1038/s41467-017-02776-7 |
0.392 |
|
| 2012 |
Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, Dutton JW, Lee HM, Chen X, Jin J, Bridges AS, Zylka MJ, Roth BL, Philpot BD. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 481: 185-9. PMID 22190039 DOI: 10.1038/Nature10726 |
0.589 |
|
| 2011 |
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, ... ... Allen JA, et al. Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences. 1236: 30-43. PMID 22032400 DOI: 10.1111/J.1749-6632.2011.06216.X |
0.372 |
|
| 2011 |
Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proceedings of the National Academy of Sciences of the United States of America. 108: 18488-93. PMID 22025698 DOI: 10.1073/Pnas.1104807108 |
0.699 |
|
| 2011 |
Allen JA, Roth BL. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annual Review of Pharmacology and Toxicology. 51: 117-44. PMID 20868273 DOI: 10.1146/annurev-pharmtox-010510-100553 |
0.506 |
|
| 2010 |
Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL. HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia. Chemmedchem. 5: 1221-5. PMID 20533502 DOI: 10.1002/Cmdc.201000186 |
0.551 |
|
| 2010 |
Dong S, Allen JA, Farrell M, Roth BL. A chemical-genetic approach for precise spatio-temporal control of cellular signaling. Molecular Biosystems. 6: 1376-80. PMID 20532295 DOI: 10.1039/C002568M |
0.654 |
|
| 2010 |
Strachan RT, Allen JA, Sheffler DJ, Roth BL. p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry. 49: 2657-71. PMID 20136148 DOI: 10.1021/bi901921k |
0.73 |
|
| 2009 |
Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proceedings of the National Academy of Sciences of the United States of America. 106: 19575-80. PMID 19889983 DOI: 10.1073/Pnas.0905884106 |
0.541 |
|
| 2009 |
Allen JA, Yu JZ, Dave RH, Bhatnagar A, Roth BL, Rasenick MM. Caveolin-1 and lipid microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase signaling. Molecular Pharmacology. 76: 1082-93. PMID 19696145 DOI: 10.1124/Mol.109.060160 |
0.696 |
|
| 2009 |
Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, McNamara JO, Roth BL. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 63: 27-39. PMID 19607790 DOI: 10.1016/J.Neuron.2009.06.014 |
0.716 |
|
| 2009 |
Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Molecular Pharmacology. 76: 710-22. PMID 19570945 DOI: 10.1124/Mol.109.058057 |
0.756 |
|
| 2009 |
Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Wetsel WC, Mosier PD, Westkaemper RB, Allen JA, Zjawiony JK, Roth BL. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry. 48: 6898-908. PMID 19555087 DOI: 10.1021/Bi900605N |
0.549 |
|
| 2009 |
Yu JZ, Dave RH, Allen JA, Sarma T, Rasenick MM. Cytosolic Gαs acts as an intracellular messenger to increase microtubule dynamics and promote neurite outgrowth Journal of Biological Chemistry. 284: 10462-10472. PMID 19237344 DOI: 10.1074/Jbc.M809166200 |
0.575 |
|
| 2008 |
Allen JA, Yadav PN, Roth BL. Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology. 55: 961-8. PMID 18640136 DOI: 10.1016/j.neuropharm.2008.06.048 |
0.535 |
|
| 2007 |
Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling Nature Reviews Neuroscience. 8: 128-140. PMID 17195035 DOI: 10.1038/Nrn2059 |
0.577 |
|
| 2005 |
Allen JA, Yu JZ, Donati RJ, Rasenick MM. β-adrenergic receptor stimulation promotes Gαs internalization through lipid rafts: A study in living cells Molecular Pharmacology. 67: 1493-1504. PMID 15703379 DOI: 10.1124/Mol.104.008342 |
0.644 |
|
| Show low-probability matches. |